ArcherDX Revenue and Competitors
Estimated Revenue & Valuation
- ArcherDX's estimated annual revenue is currently $2.9M per year.
- ArcherDX received $35.0M in venture funding in March 2018.
- ArcherDX's estimated revenue per employee is $95,000
- ArcherDX's total funding is $150M.
Employee Data
- ArcherDX has 31 Employees.
- ArcherDX grew their employee count by -24% last year.
ArcherDX Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.7M | 11 | 0% | N/A | N/A |
#2 | $0.9M | 15 | 15% | N/A | N/A |
#3 | $63.7M | 365 | 5% | N/A | N/A |
#4 | $1.7M | 24 | 4% | N/A | N/A |
#5 | $1.6M | 26 | 0% | N/A | N/A |
#6 | N/A | 19 | 58% | N/A | N/A |
#7 | $0.7M | 11 | -31% | N/A | N/A |
#8 | $0.9M | 15 | 50% | N/A | N/A |
#9 | $7.8M | 43 | 8% | N/A | N/A |
#10 | $1.9M | 24 | -8% | N/A | N/A |
What Is ArcherDX?
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types. By combining novel enrichment chemistry, automated informatics and a user-friendly workflow, Archer products remove the bottlenecks associated with using next-gen sequencing in a translational setting.
keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals$150M
Total Funding
31
Number of Employees
$2.9M
Revenue (est)
-24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ArcherDX News
... Genapsys Inc. has operations in Westminster; Invitae Corp., a medical-genetics company, acquired Boulder-based ArcherDX in late 2020;...
Close has served as an executive leader in both diagnostic and pharmaceutical companies, including at ArcherDX/Invitae and Eli Lilly, among...
... Growth Opportunity and Forecast 2022-2028 | Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG,.
Boulder's ArcherDX, a biotech company developing personalized genomic medicine, announced it closed a $55 million Series C round to grow its commercial footprint and further its product offerings. The round was led by Perceptive Advisors, which was joined by new investors Redmile Group, Soleus ...
ArcherDX, Inc., a Boulder, Colo.-based molecular diagnostics company dedicated to developing solutions that advance the application of personalized genomic medicine, closed a $55m Series C financing. The round was led by Perceptive Advisors, which was joined by new investors Redmile Group, Sole ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.7M | 31 | 3% | N/A |
#2 | $8.6M | 31 | 19% | N/A |
#3 | $3.6M | 31 | 15% | $8.4M |
#4 | $8.6M | 31 | 19% | N/A |
#5 | $8.9M | 31 | 35% | N/A |
ArcherDX Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2018-03-21 | $35.0M | A | Boulder Ventures, Ltd. | Article |